Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00818493 · ClinicalTrials.gov registry record · Phase 2

Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty

A Phase 2 study, sponsored by QRxPharma.

Completed
Registry status
Phase 2
Development phase
44
Enrollment target

NCT00818493 is a Phase 2 study that has completed, run by QRxPharma. The registered enrollment target is 44 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00818493, a Phase 2 study, has completed, sponsored by QRxPharma.

COMPLETED
Registry status
Phase 2
Development phase
44 participants
Enrollment target

Study Summary

This is a Phase 2 3-arm, open label pilot study of the safety and efficacy of Q8003 in patients who have undergone primary unilateral total knee arthroplasty or total hip arthroplasty.

Interventions

  • DRUG Q8003 (morphine sulfate and oxycodone hydrochloride)
  • DRUG Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
  • DRUG Percocet (oxycodone and acetaminophen)

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2009-02
Est. Completion 2009-07
Phase Phase 2

Sponsor

QRxPharma

7 total trials

What the Registry Record Tells You About NCT00818493

The ClinicalTrials.gov registry entry for NCT00818493 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is QRxPharma, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Q8003 (morphine sulfate and oxycodone hydrochloride) is the first listed.

NCT00818493 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00818493 about?

NCT00818493 is a clinical study titled "Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty". This is a Phase 2 3-arm, open label pilot study of the safety and efficacy of Q8003 in patients who have undergone primary unilateral total knee arthroplasty or total hip arthroplasty.

What is the current status of trial NCT00818493?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2009-02. Estimated completion is 2009-07.

What interventions are being tested in trial NCT00818493?

The interventions under investigation include: Q8003 (morphine sulfate and oxycodone hydrochloride) (DRUG), Low dose Q8003 (morphine sulfate and oxycodone hydrochloride) (DRUG), Percocet (oxycodone and acetaminophen) (DRUG).

Who is sponsoring clinical trial NCT00818493?

This trial is sponsored by QRxPharma, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.